$AMGN
AMGN · Healthcare
- Market cap
- —
- Volume
- —
- P/E
- —
- Day range
- — – —
- 52w range
- — – —
- Analyst target
- —
AI Summary
Generating a unique summary for AMGN…
AI-generated for information only — not investment advice.
Share this ticker
$AMGN Warren Buffett and 2 other tracked billionaires hold it. $JNJ $NTRA $LLY https://billionairestrading.com/stocks/AMGN
Company summary
Biotech, Enbrel and Repatha.
Institutional ownership
Institutions hold —% · insiders —%
No institutional filings available for this ticker.
Hedge fund & billionaire activity
Insider transactions
No insider transactions reported.
Analyst ratings
Consensus score — (1 = strong buy, 5 = sell) · mean target —
No recent analyst actions.
Earnings
Next report: not scheduled
No earnings history available.
SEC filings
No filings indexed for this ticker.
Latest AMGN news
- Amgen's 7,297-Patient Heart Bet Just Inherited a Higher Bar
Novartis lowered the target biomarker without reducing events; olpasiran must prove the mechanism can still deliver.
Mon, 07 Sep 2026 21:46:39 +0000
- Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.
Mon, 07 Sep 2026 15:23:00 +0000
- Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence Now Available. Tracks 870+ Organizations and 1,400+ Drugs Across the Full Bi/Multispecific Oncology Pipeline
One-Year Analytical Tool Delivers Near-Real-Time Pipeline Alerts on 481 Targets, 350 Deals, and 1,100+ Funding Rounds as Amgen, Roche, and J&J Lead a Field That Saw 278 New Drugs in 2024/25 AloneDublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence" has been added to ResearchAndMarkets.com's offering. Bi/Multispecific Drugs in Oncology Analytical Tool Delivers Near-Real-Time Intelligence for Oncology Drug
Mon, 07 Sep 2026 10:00:00 +0000
- Amgen (AMGN) Says Repatha Reduced Mortality Before a First Heart Attack or Stroke. Can Earlier Use Expand the Market?
Amgen Inc. (NASDAQ:AMGN) reported that Repatha reduced the risk of all-cause mortality by 20% in a prespecified secondary analysis of the Phase 3 VESALIUS-CV trial. The study enrolled more than 12,000 high-risk adults without a previous heart attack or stroke and followed them for a median of 4.6 years. The mortality reduction began to appear […]
Fri, 04 Sep 2026 15:59:14 +0000
- AMGN's MariTide: Can Convenience Drive its Obesity Market Share?
Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.
Fri, 04 Sep 2026 13:05:00 +0000
- Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Thu, 03 Sep 2026 15:30:06 +0000
- TEZSPIRE’s Positive EoE Phase 3 Results Could Be A Game Changer For Amgen (AMGN)
Amgen and AstraZeneca recently reported positive Phase 3 CROSSING results showing TEZSPIRE improved histologic remission and dysphagia symptoms in patients with eosinophilic esophagitis, with effects sustained through week 52 and a safety profile broadly consistent with prior use. Because EoE remains poorly controlled for nearly half of patients on existing therapies, TEZSPIRE’s epithelial-targeting mechanism could meaningfully expand its role beyond severe asthma and nasal polyps if...
Wed, 02 Sep 2026 21:09:18 +0000
- Amgen Stock Signals Its Confidence. The Market Agrees.
The real bet is on what lies beyond this year's performance: a pipeline that could change everything.
Wed, 02 Sep 2026 20:55:36 +0000